November 24, 2025

Vertero Initiates Phase 1 Study of VT-5006, A Selective Small Molecule Therapy for Parkinson’s Disease

October 21, 2025

Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases